Pancreatic cancer pill nearly doubles survival

Pancreatic cancer that has spread is one of the hardest diagnoses in oncology. On 26 August, the US Food and Drug Administration approved daraxonrasib, a daily pill that in a phase III trial extended median survival to 13.2 months versus 6.7 months with standard chemotherapy. That trial enrolled patients whose metastatic pancreatic cancer had worsened after one prior treatment. The FDA's approval is broader: it covers adults with metastatic pancreatic adenocarcinoma after at least one systemic therapy, and also those unable to tolerate multiagent chemotherapy, a group not directly studied in the randomised comparison.

The FDA called daraxonrasib a "first-in-class targeted therapy for metastatic pancreatic cancer", sold as RASONQUE by Revolution Medicines. The approval rested on a completed phase III trial published in the New England Journal of Medicine, not a surrogate measure or early-stage signal.

Why this protein was so hard to target

Most pancreatic cancers are driven by mutations in a protein called KRAS. Think of KRAS as a light switch inside cells: it flips on to relay a growth signal, then turns itself off. Cancer-causing mutations jam the switch permanently on, flooding cells with grow-and-divide instructions.

Scientists identified this problem in the 1980s but couldn't design a drug to stop it. The protein's surface is unusually smooth, lacking the deep grooves where medicines typically lodge.

In 2013, researchers found a hidden pocket on one specific mutant form called KRAS-G12C. (The letter-number labels identify different changes at the same position in the protein.) That discovery led to approved drugs, but they work only against that single variant. The mutations that dominate in pancreatic cancer, named G12D, G12V and G12R, remained out of reach.

Daraxonrasib works differently. According to a 2024 study describing its mechanism, the drug first attaches to cyclophilin A, a protein abundant in cells. That two-part complex then binds to active RAS, preventing it from relaying its growth signal. Because this approach targets a surface shared across several RAS variants rather than a mutation-specific pocket, it can engage the forms most common in pancreatic tumours.

What the trial measured

The RASolute 302 trial randomised 500 patients across international centres, comparing daraxonrasib against the physician's choice among four standard chemotherapy regimens. Patients had metastatic pancreatic cancer that had progressed after one prior treatment and were physically well enough to carry out light activity and self-care.

The results were unusually clear for this disease. One-year survival in the dominant RAS-G12 group reached 53.3% versus 18.7% with chemotherapy. The hazard ratio for death was 0.40, meaning the estimated rate of death during follow-up was substantially lower with daraxonrasib. Tumour scans, assessed by blinded reviewers, showed objective shrinkage in about 30% of daraxonrasib patients versus 11% on chemotherapy.

Side effects were common. According to the prescribing label, rash occurred in about 85% of patients, diarrhoea in 58%, and mouth sores in 53%. Severe toxicity and treatment discontinuation rates were lower than with chemotherapy, and patients reported significantly delayed worsening of pain.

These are population-level statistics from comparatively fit patients after exactly one prior treatment. They don't guarantee any individual the same benefit. Follow-up was a median of 8.5 months, so longer-term durability is still being measured.

European access remains distant

The FDA decision carries no legal weight in the EU. The European Medicines Agency began a phased assessment in July 2026 under its Cancer Medicines Pathfinder, evaluating data before a full marketing application is submitted. As of early September, no complete application had appeared in public records, no approval timeline had been given, and EMA cautioned that its overall timetable "could not yet be anticipated." Daraxonrasib also received EU orphan designation for pancreatic cancer in April, a regulatory incentive distinct from authorisation. Even after a positive EU decision, national pricing and reimbursement would determine when patients in individual countries could actually receive the drug.

For comparatively fit patients whose metastatic pancreatic cancer progressed after one treatment, daraxonrasib improved survival over chemotherapy in a rigorous trial. Early lung-cancer data from the same compound showed response rates of 31–37%, with phase III trials underway. Preclinical models suggest several possible resistance routes, though whether they prove important in patients is unknown. Whether European regulators approve the drug, and when national health systems might provide it, remains unresolved.